Lataa...
Immunotherapy in ovarian cancer
Ovarian cancer is the most deadly gynecologic malignancy, with more than 15,000 deaths anticipated in 2012.(1) While approximately 80% of patients will respond to frontline chemotherapy, more than 60% of patients will experience disease recurrence and only 44% will be alive at 5 years.(1)(,)(2) Host...
Tallennettuna:
| Päätekijät: | , , |
|---|---|
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Landes Bioscience
2012
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3579897/ https://ncbi.nlm.nih.gov/pubmed/22906947 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4161/hv.20738 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|